The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
Open accessAbstract
Background: Patients with meningiomas have widely divergent clinical courses. Some entirely recover following surgery alone, while others have relentless tumor recurrences. This clinical conundrum is exemplified by rhabdoid meningiomas, which are designated in the World Health Organization Classification of Tumours as high grade, despite only a subset following an aggressive clinical course. Patient management decisions are further exacerbated by high rates of interobserver variability, biased against missing possibly aggressive tumors. Objective molecular determinants are needed to guide classification and clinical decision making. Methods: To define genomic aberrations of rhabdoid meningiomas, we performed sequencing of cancer-related genes in 27 meningiomas from 18 patients with rhabdoid features and evaluated breast cancer [BRCA]1-associated protein 1 (BAP1) expression by immunohistochemistry in 336 meningiomas. We assessed outcomes, germline status, and family history in patients with BAP1-negative rhabdoid meningiomas. Results: The tumor suppressor gene BAP1, a ubiquitin carboxy-terminal hydrolase, is inactivated in a subset of high-grade rhabdoid meningiomas. Patients with BAP1-negative rhabdoid meningiomas had reduced time to recurrence compared with patients with BAP1-retained rhabdoid meningiomas (Kaplan-Meier analysis, 26 mo vs 116 mo, P < .001; hazard ratio 12.89). A subset of patients with BAP1-deficient rhabdoid meningiomas harbored germline BAP1 mutations, indicating that rhabdoid meningiomas can be a harbinger of the BAP1 cancer predisposition syndrome. Conclusion: We define a subset of aggressive rhabdoid meningiomas that can be recognized using routine laboratory tests. We implicate ubiquitin deregulation in the pathogenesis of these high-grade malignancies. In addition, we show that familial and sporadic BAP1-mutated rhabdoid meningiomas are clinically aggressive, requiring intensive clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating common and rare genetic variation in diverse human populations
The International HapMap 3 Consortium (2010) · Nature · doi:10.1038/nature09298 · Cited by 3,026
Research works printed but not linked: 43
- Louis DN Ohgaki H Wiestler OD WHO Classification of Tumours of the Central Nervous System . Revised 4th ed. Lyon, France: International Agency for Research on Cancer; 2016:232–257.
- 10.18632/oncotarget.2517 · DOI
- 10.1038/ng.2526 · DOI · Paper page
- 10.1126/science.1233009 · DOI · Paper page
- 10.1007/s00401-013-1093-x · DOI · Paper page
- 10.1038/ng.2552 · DOI · Paper page
- 10.1093/neuonc/nov316 · DOI · Paper page
- 10.1016/0092-8674(93)90406-G · DOI · Paper page
- 10.1002/path.4427 · doi:10.1002/path.4427
- 10.1097/00000478-199802000-00012 · doi:10.1097/00000478-199802000-00012
- 10.1097/00000478-199812000-00005 · doi:10.1097/00000478-199812000-00005
- Vaubel, 2016, Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature, J Neuropathol Exp Neurol, 75, 44, 10.1093/jnen/nlv006 · DOI
- 10.1093/neuonc/nov247 · DOI
- 10.1016/j.cancergen.2015.03.005 · DOI
- 10.1038/ng.806 · DOI · Paper page
- 10.1101/gr.107524.110 · DOI · Paper page
- 10.1038/nbt.2514 · DOI · Paper page
- 10.1016/j.ajhg.2009.11.004 · DOI · Paper page
- 10.1038/nbt.2203 · DOI · Paper page
- 10.1038/nature09744 · DOI · Paper page
- 10.1093/bioinformatics/btr446 · DOI · Paper page
- 10.1093/bioinformatics/bts271 · DOI · Paper page
- 10.1158/2159-8290.CD-15-0369 · DOI · Paper page
- 10.1371/journal.pone.0038881 · DOI
- 10.1038/nrc3459 · DOI · Paper page
- 10.1038/nm.3739 · DOI · Paper page
- 10.1038/ncomms10086 · DOI · Paper page
- 10.1136/jmedgenet-2011-100156 · DOI · Paper page
- de la Fouchardiere, 2015, Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome, Acta Neuropathol, 129, 921, 10.1007/s00401-015-1423-2 · DOI
- 10.1016/j.ajhg.2013.04.012 · DOI · Paper page
- 10.1038/ng.912 · DOI · Paper page
- 10.1097/JTO.0000000000000471 · DOI · Paper page
- 10.1038/ng.3520 · DOI · Paper page
- van de Nes, 2016, Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma, Am J Surg Pathol, 40, 796, 10.1097/PAS.0000000000000645 · DOI
- 10.1111/bpa.12174 · DOI
- Sahm F Schrimpf D Olar A . TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):. · DOI · Paper page
- 10.1111/bpa.12110 · DOI · Paper page
- Perry, 2002, A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas, Brain Pathol, 12, 183, 10.1111/j.1750-3639.2002.tb00433.x · doi:10.1111/j.1750-3639.2002.tb00433.x
- 10.1016/S0002-9440(10)61737-3 · DOI · Paper page
- 10.1093/neuonc/nov177 · DOI
- 10.1093/neuonc/not325 · doi:10.1093/neuonc/not325
- 10.1038/ng.2323 · DOI · Paper page
- 10.1038/nm.3947 · DOI · Paper page
Cited by
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Self-citationMeningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions
Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030319 · Cited by 324
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole, S., Pritchard, A. L., Cebulla, C. M., Pilarski, R., Stautberg, M., Davidorf, F. H., de la Fouchardière, A., Cabaret, O., Golmard, L., Stoppa-Lyonnet, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy171 · Cited by 253
Self-citation
Metadata
- Authors
- Shankar, G. M., Abedalthagafi, M., Vaubel, R. A., Merrill, P. H., Nayyar, N., Gill, C. M., Brewster, R., Bi, W. L., Agarwalla, P. K., Thorner, A. R., Reardon, D. A., Al-Mefty, O., Wen, P. Y., Alexander, B. M., van Hummelen, P., Batchelor, T. T., Ligon, K. L., Ligon, A. H., Meyerson, M., Dunn, I. F., Beroukhim, R., Louis, D. N., Perry, A., Carter, S. L., Giannini, C., Curry, W. T., Cahill, D. P., Barker, F. G., Brastianos, P. K., & Santagata, S.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-11-10
- Volume
- 19
- Issue
- 4
- Pages
- now235
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2554212574
- Cited by
- 184
- References
- 1
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- King Abdulaziz City for Science and Technology (110968)
- Susan G. Komen for the Cure
- Conquer Cancer Foundation
- American Brain Tumor Association
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. https://app.cochat.ai/papers/10.1093/neuonc/now235
- The paper
- Shankar, G. M., Abedalthagafi, M., Vaubel, R. A., Merrill, P. H., Nayyar, N., Gill, C. M., Brewster, R., Bi, W. L., Agarwalla, P. K., Thorner, A. R., Reardon, D. A., Al-Mefty, O., Wen, P. Y., Alexander, B. M., van Hummelen, P., Batchelor, T. T., Ligon, K. L., Ligon, A. H., Meyerson, M., . . . Santagata, S. (2016). Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/now235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.